BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27474927)

  • 1. Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.
    Lawson M; Rodrigo J; Baratte B; Robert T; Delehouzé C; Lozach O; Ruchaud S; Bach S; Brion JD; Alami M; Hamze A
    Eur J Med Chem; 2016 Nov; 123():105-114. PubMed ID: 27474927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines.
    Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S
    Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
    Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
    Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.
    Zeinyeh W; Esvan YJ; Josselin B; Baratte B; Bach S; Nauton L; Théry V; Ruchaud S; Anizon F; Giraud F; Moreau P
    Bioorg Med Chem; 2019 May; 27(10):2083-2089. PubMed ID: 30967303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Kinase Inhibitors via Metal-Catalyzed C⁻H Arylation of 8-Alkyl-thiazolo[5,4-
    Couly F; Harari M; Dubouilh-Benard C; Bailly L; Petit E; Diharce J; Bonnet P; Meijer L; Fruit C; Besson T
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30158487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.
    Waiker DK; Karthikeyan C; Poongavanam V; Kongsted J; Lozach O; Meijer L; Trivedi P
    Bioorg Med Chem; 2014 Mar; 22(6):1909-15. PubMed ID: 24530227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
    Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
    Zhou Q; Reekie TA; Abbassi RH; Indurthi Venkata D; Font JS; Ryan RM; Munoz L; Kassiou M
    Bioorg Med Chem; 2018 Dec; 26(22):5852-5869. PubMed ID: 30401502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.
    Terao Y; Suzuki H; Yoshikawa M; Yashiro H; Takekawa S; Fujitani Y; Okada K; Inoue Y; Yamamoto Y; Nakagawa H; Yao S; Kawamoto T; Uchikawa O
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7326-9. PubMed ID: 23147077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity.
    Gourdain S; Dairou J; Denhez C; Bui LC; Rodrigues-Lima F; Janel N; Delabar JM; Cariou K; Dodd RH
    J Med Chem; 2013 Dec; 56(23):9569-85. PubMed ID: 24188002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives.
    Zeinyeh W; Esvan YJ; Nauton L; Loaëc N; Meijer L; Théry V; Anizon F; Giraud F; Moreau P
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4327-9. PubMed ID: 27469128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
    Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors.
    Park A; Hwang J; Lee JY; Heo EJ; Na YJ; Kang S; Jeong KS; Kim KY; Shin SJ; Lee H
    Bioorg Med Chem Lett; 2021 Sep; 47():128226. PubMed ID: 34182093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
    Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines.
    Buckley GM; Fosbeary R; Fraser JL; Gowers L; Higueruelo AP; James LA; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3656-60. PubMed ID: 18501603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.
    Yadav RR; Sharma S; Joshi P; Wani A; Vishwakarma RA; Kumar A; Bharate SB
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2948-52. PubMed ID: 26048785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.